Acrisure Capital Management’s Biogen BIIB Stock Holding History

Acrisure Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,036	Closed	-$288K	–	28
2023 Q1	$288K	Buy	+1,036	New	+$287K	0.29%	146

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Acrisure Capital Management's BIIB Position: Q2 2023 in Review

Acrisure Capital Management sold out of Biogen (BIIB) in Q2 2023, closing a stake of 1,036 shares — an estimated $288K sold.

Acrisure Capital Management first reported a position in BIIB in Q1 2023 and held it in 1 quarter. The position peaked at $288K in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

Acrisure Capital Management reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
Acrisure Capital Management sold 1,036 Biogen shares in Q2 2023, an estimated $288K.
Acrisure Capital Management first reported a position in Biogen in Q1 2023 and held it in 1 quarter.
Acrisure Capital Management's Biogen position peaked at $288K in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Acrisure Capital Management's 13F filing for Q2 2023.